1. Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)
Figure 1 | Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown). Statins inhibit cholesterol synthesis in the liver, ezetimibe blocks cholesterol absorption in the intestine, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors block the PCSK9-mediated degradation of LDL receptors.
Grundy, S. M. (2016) Advances in treatment of dyslipidaemia
Nat. Rev. Cardiol. doi: /nrcardio